Molnupiravir

Also known as EIDD-2801 or MK-4482. KEI Blogs 2021. October 22. Countries included in the Merck/molnupiravir license. 2021. October 20. International landscape of molnupiravir patents. 2021. October 4. U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts… Continue Reading

KEI and UACT Joint Comments to the NIH Regarding Exclusive License to Syncopation for CAR Therapy

Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) on Friday July 9, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific… Continue Reading

Biden Administration asked to clarify scope of sanctions exceptions for Cuba’s vaccine program, and to support the evaluation and registration of its COVID-19 vaccines

On June 28, 2021, KEI sent a memorandum to Gayle E Smith (State), Eric Lander (OSTP), Loyce Pace (HHS) and Samantha Power (USAID), asking the U.S. government to clarify that its sanctions against Cuba do not extend to activities and… Continue Reading

KEI submission to Canada Standing Committee on International Trade and Investment Policy: Concerning COVID-19

Brief to Standing Committee on International Trade and Investment Policy: Selected Consideration Concerning COVID-19 Vaccines Knowledge Ecology International James Love and Arianna Schouten 30 April 2021 This brief will discuss (1) the scope and purpose of the proposed World Trade… Continue Reading